Fresh analysis suggests that patients who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who stop traditional diet and exercise plans.
Findings released in a major medical journal demonstrates that while obese people frequently drop about a fifth of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying such medications should be aware of the potential of rapid weight regain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about 18 months.
Analyzing Treatments
The study, which looked at 37 of trials involving over 9,000 of participants, compared the results of the injectable medications with other pills.
Researchers emphasize that people who lose weight through dieting generally have a more gradual weight regain—around 100 grams monthly—post-intervention.
Explaining the Fast Regain
Doctors suggest the mechanism of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Disease?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, given the significant potential of relapse, the therapy might need to be long-term.
This opinion is echoed by pharmaceutical companies, who say that the findings "emphasize the chronic nature of obesity," akin to managing conditions like hypertension.
User Accounts
Individuals who have discontinued the medication describe a powerful resurgence of cravings.
"I experienced a switch activating and you become ravenous," said one woman.
This difficulty is compounded if patients have not developed sustainable lifestyle or habit changes during treatment.
Widespread Adoption
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is greater among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, experts stress that while these medications are powerful agents for shedding pounds, they are not a standalone cure and long-term success likely depends on integrated behavioural management.
